Next Article in Journal
2, 3, 4′, 5-tetrahydroxystilbene-2-0-β-d Glycoside Attenuates Age- and Diet-Associated Non-Alcoholic Steatohepatitis and Atherosclerosis in LDL Receptor Knockout Mice and Its Possible Mechanisms
Next Article in Special Issue
The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Restores Cardiomyocyte Contractility in a Rat Model of Early Diabetes
Previous Article in Journal
Cytological and Proteomic Analysis of Wheat Pollen Abortion Induced by Chemical Hybridization Agent
Previous Article in Special Issue
HDAC6 Modulates Signaling Pathways Relevant to Synaptic Biology and Neuronal Differentiation in Human Stem Cell-Derived Neurons
Open AccessReview

Mechanism of Action for HDAC Inhibitors—Insights from Omics Approaches

by 1,2 and 1,2,*
1
Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
2
Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(7), 1616; https://doi.org/10.3390/ijms20071616
Received: 10 March 2019 / Revised: 26 March 2019 / Accepted: 27 March 2019 / Published: 1 April 2019
(This article belongs to the Special Issue Histone Deacetylase Inhibitors in Health and Disease)
Histone deacetylase inhibitors (HDIs) are a class of prominent epigenetic drugs that are currently being tested in hundreds of clinical trials against a variety of diseases. A few compounds have already been approved for treating lymphoma or myeloma. HDIs bind to the zinc-containing catalytic domain of the histone deacetylase (HDACs) and they repress the deacetylase enzymatic activity. The broad therapeutic effect of HDIs with seemingly low toxicity is somewhat puzzling when considering that most HDIs lack strict specificity toward any individual HDAC and, even if they do, each individual HDAC has diverse functions under different physiology scenarios. Here, we review recent mechanistic studies using omics approaches, including epigenomics, transcriptomics, proteomics, metabolomics, and chemoproteomics, methods. These omics studies provide non-biased insights into the mechanism of action for HDIs. View Full-Text
Keywords: histone deacetylase inhibitors (HDIs); epigenomics; transcriptomics; proteomics; metabolomics; chemoproteomics; cancer treatment histone deacetylase inhibitors (HDIs); epigenomics; transcriptomics; proteomics; metabolomics; chemoproteomics; cancer treatment
Show Figures

Figure 1

MDPI and ACS Style

Li, W.; Sun, Z. Mechanism of Action for HDAC Inhibitors—Insights from Omics Approaches. Int. J. Mol. Sci. 2019, 20, 1616. https://doi.org/10.3390/ijms20071616

AMA Style

Li W, Sun Z. Mechanism of Action for HDAC Inhibitors—Insights from Omics Approaches. International Journal of Molecular Sciences. 2019; 20(7):1616. https://doi.org/10.3390/ijms20071616

Chicago/Turabian Style

Li, Wenbo; Sun, Zheng. 2019. "Mechanism of Action for HDAC Inhibitors—Insights from Omics Approaches" Int. J. Mol. Sci. 20, no. 7: 1616. https://doi.org/10.3390/ijms20071616

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop